On March 24, 2026 Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, reported that a multi-year Joint Research Collaboration Agreement has been established with the Universities of Jaén (UJA) and Granada (UGR), Spain. This is the fifth agreement between Propanc and the universities over a seventeen-year period resulting in four patent families being filed, five peer reviewed publications accepted, numerous scientific presentations delivered, as well as two PhD’s and a professorship awarded to members of the Universities’ research team members.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The collaboration involves the evaluation of a senescence-modulating (i.e., anti-aging) compound to mitigate senescence and to complete experiments to further support the claims of recently filed fibrosis and cancer related patent applications, requested by Propanc Biopharma Inc. to the research group "Biological Technologies of The University of Jaén" and UGR’s Research Group, "Advanced Therapies: Differentiation, Regeneration and Cancer."
Prof. Macarena Perán Quesada, University of Jaén, will oversee management and coordination functions of the working team and will be the scientist in charge of the project appointed by the university. Two Postdoctoral Fellows of the UJA, Dr Maria Belén Toledo and Dr Aitor González-Titos will conduct the study, including in vitro and in vivo experiments, data analysis, and manuscript preparation.
Prof. Juan Antonio Marchal Corrales, head of the Laboratory in Bio-fabrication and 3D-bioprinting of the University of Granada will oversee management of equipment and facilities necessary to perform in vitro and in vivo experiments and will be the scientist in charge of the experimental designs and project by the university.
"As we enter an exciting phase for the Company advancing our lead asset, PRP to a Phase 1b, First-In-Human study in advanced cancer patients this year, we are delighted to strengthen our collaboration with our partner universities, specifically Professors Quesada and Marchal and the research team. Over the next two years, our goal is to strengthen our intellectual property and to better understand how PRP technology can overcome numerous resistant tumors, and additionally, rejuvenate cells to overcome age-related, chronic diseases, such as fibrosis," said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. "The market potential of PRP is significant and of a high degree of interest among the scientific community. As we transform into a clinical-stage R&D Company we look forward to possible major discoveries that broadens the therapeutic potential of PRP in several life-threatening diseases based on cell and tissue rejuvenation."
(Press release, Propanc, MAR 24, 2026, View Source [SID1234663870])